Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing innovative, targeted oncology drugs, today announces that the Company will present an updated data analysis from the Phase 1a trial of FAP-Dox (AVA6000) at the 2025 European Society for Medical Oncology (ESMO) Congress, in Berlin, Germany, taking place from October 17-21, 2025. AVA6000 is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the tumor microenvironment.
The poster presentation will be based on the most recent data analysis from the Phase 1a trial of FAP-Dox (AVA6000) in patients with Fibroblast Activation Protein (FAP)-positive solid tumors. Avacta completed the Phase 1a enrollment dose escalation portion of the clinical trial in late 2024, with patient enrollment ongoing in multiple dose expansion cohorts of a Phase 1b study.
Abstract details are listed below and available online on the ESMO website.
Avacta will hold an investor event shortly after the ESMO presentation. Further details will be made available nearer the time.
Title: A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
Session Title: Developmental Therapeutics
Session Date and Time: 17 October, 19:40 – 20:00
Location: Berlin Auditorium – Hub 27
Abstract Presentation Number: 964P
Speaker: William D. Tap